Tempus AI rises after study shows AI-driven alerts improve heart valve treatment

Shares of genetics-testing firm Tempus AI TEM.O rise 3.56% to $46.83

Co says a collaboration study with medical device maker Medtronic MDT.N showed AI-driven alerts sent through electronic health records improved timely evaluation and treatment of patients with aortic stenosis or mitral regurgitation, two serious heart valve diseases

Study showed patients in the alert group were 27% more likely to be evaluated by a specialist heart team or receive a valve procedure than those getting usual care, meeting its main goal - TEM

Within 90 days of the heart scan, the alerts raised valve procedures to 13.4% from 9.6% and specialist heart team evaluations to 22.7% from 17.9% - TEM

TEM shares rose over 74% in 2025